Biotechnology company Sareum Holdings plc (AIM: SAR) announced on Monday that it has completed dosing in the Phase 2-enabling toxicology programme for SDC-1801, its selective oral TYK2/JAK1 inhibitor being developed for autoimmune diseases, initially targeting psoriasis.
Following the programme's restart in February 2026, Sareum said the dosing phase was completed in line with expectations. The company is now analysing data and progressing chemistry, manufacturing and controls and formulation activities.
Sareum expects to complete the full Phase 2-enabling regulatory package by the fourth quarter of 2026 using existing cash resources.
argenx agrees to acquire Forte Biosciences for USD2.2bn to add anti-CD122 antibody FB102
Sareum completes dosing in Phase 2-enabling toxicology programme for SDC-1801
FDA grants priority review to Genentech's Gazyva for primary membranous nephropathy
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Antengene receives USD60m upfront payment from UCB
Teva and Polpharma Biologics enter global licensing agreement for biosimilar candidate to Ocrevus
United Therapeutics acquires Thymmune Therapeutics to expand regenerative cell therapy pipeline
AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata
AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo
Japan approves Wayrilz for immune thrombocytopenia treatment
Minghui Pharmaceutical presents MHB018A Phase I/II results for thyroid eye disease at ENDO 2026
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19